• Minerva Neurosciences highlighted roluperidone as a potential first treatment targeting primary negative symptoms of schizophrenia, an area with no FDA-approved therapies.
• Confirmatory Phase 3 C19 trial is actively enrolling; topline 12-week efficacy data expected in 2H 2027, with a 52-week safety/relapse assessment.
• Trial design targets about 380 patients across about 40 sites in the U.S. and four European countries; 64 mg dose versus placebo for primary analysis.
• Company cited prior registrational studies showing improvement on negative symptoms and functioning at 64 mg, with stable positive symptoms and low relapse rates.
• Financing of USD 200 million in October 2025 is expected to fund operations through C19 data readout and NDA submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief on June 05, 2026, and is solely responsible for the information contained therein.